AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
MWN-AI** Summary
AIM ImmunoTech Inc. (NYSE American: AIM) has announced the appointment of David Chemerow as an Independent Director to its Board, effective immediately. Chemerow brings over 40 years of extensive leadership experience in finance, accounting, and operations across various sectors. His significant prior roles include serving as Chief Financial Officer and Treasurer of Comscore, Inc., a global media measurement and analytics company, and as Chief Operating Officer and CFO of Rentrak Corporation during its merger with Comscore in 2016.
In addition to his corporate roles, Chemerow is actively involved in governance and advisory capacities. He currently sits on the Board of Directors of Dunham’s Athleisure Corporation and the Advisory Board of Huntington Outdoor, LLC. His community engagement includes roles with non-profit organizations, including being on the Board of The Martha’s Vineyard Playhouse and serving as President of the Pilot Hill Farm Association. Chemerow has previously contributed to the boards of RiceBran Technologies and Playboy Enterprises.
AIM ImmunoTech's Board Chairman, Dr. William Mitchell, expressed confidence in Chemerow’s leadership and financial expertise, asserting that his skills would significantly support AIM’s mission for upcoming growth. Chemerow highlighted his belief in AIM's potential within the immuno-pharma sector, particularly pointing out the promising capabilities of the product Ampligen, which is under investigation for various high-value medical indications.
AIM ImmunoTech is dedicated to developing therapies for cancers, immune disorders, and viral diseases, with its leading investigational drug, Ampligen, positioned for broad-spectrum applications in clinical trials. Investors are encouraged to review the risks outlined in AIM's regulatory filings, as the company continues its path toward growth and innovation in the pharmaceutical landscape.
MWN-AI** Analysis
AIM ImmunoTech (NYSE American: AIM) has made a strategic move by appointing David Chemerow as an Independent Director to its Board, a decision that carries significant implications for both the company and its investors. Mr. Chemerow’s extensive background, particularly his leadership roles in finance and operations at Comscore and Rentrak, signals a shift towards stronger financial oversight and strategic direction that could benefit AIM as it navigates the complex immuno-pharma landscape.
As AIM seeks to advance its lead investigational drug, Ampligen, which targets various cancers and viral diseases, Mr. Chemerow’s expertise will likely enhance the company's governance. This appointment comes at a crucial time, as AIM positions itself to capitalize on the growing demand for innovative cancer treatments and immune-modulating therapies. Given the ongoing focus on immunotherapy, AIM could see increased market interest, especially as Ampligen demonstrates its potential in clinical trials.
For investors, this appointment should be viewed positively. The inclusion of a seasoned finance professional on the board may lead to improved operational efficiency and possibly better financial performance. Mr. Chemerow's previous board experience in both the public and non-profit sectors suggests he brings a wealth of knowledge that could help AIM navigate the regulatory and market challenges in the pharmaceutical industry.
Nevertheless, potential investors should remain cautious. The company’s forward-looking statements indicate inherent risks related to clinical trials and regulatory approval pathways. AIM's recent performance and market reactions should be analyzed in conjunction with broader industry trends and any updates on Ampligen’s clinical outcomes.
In summary, AIM ImmunoTech's governance enhancement through Mr. Chemerow's appointment may foster strategic growth, but investors must weigh these developments against the backdrop of the uncertainties within the biotech sector. As always, conducting thorough due diligence is essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately.
Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer and Chief Financial Officer of Rentrak Corporation through its merger with Comscore, Inc. in January 2016. Prior to 2009, Mr. Chemerow held senior executive roles leveraging his financial, business and operational expertise across multiple companies.
Mr. Chemerow currently serves on the Board of Directors for Dunham’s Athleisure Corporation, a sporting goods retailer, and on the Advisory Board of Huntington Outdoor, LLC, an outdoor advertising company. Additionally, Mr. Chemerow serves on the Board of non-profit theater, The Martha’s Vineyard Playhouse, and is President of the Board of the Pilot Hill Farm Association. Previously, Mr. Chemerow served as a member of the Board of Directors of RiceBran Technologies, Inc., a Nasdaq and OTC company, and served 15 years as a Board member of Playboy Enterprises. Mr. Chemerow is a graduate of Dartmouth College and holds a Master of Business Administration degree from The Amos Tuck School at Dartmouth College.
AIM Board of Directors Chairman William Mitchell, MD, PhD, stated: “Mr. Chemerow has a proven track record of leadership, business and financial acumen over the course of his career. His skills, experiences and qualifications will be valuable contributions to AIM’s mission as we continue to advance toward near-and long-term success. I look forward to working with him.”
Mr. Chemerow added: “I believe AIM is well positioned to be a valuable player in the immuno-pharma space. Ampligen has demonstrated potential across a number of high-value indications, and I am excited to help propel the Company to its next phase of growth.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ae8dd177-5ac1-48be-8138-8431c866af4a
Investor Contact:JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com
FAQ**
How does AIM ImmunoTech Inc. AIM plan to leverage Mr. David Chemerow's extensive experience in finance and operations to enhance its strategic direction and growth?
What specific contributions does AIM ImmunoTech Inc. AIM anticipate from Mr. Chemerow in advancing the clinical development of Ampligen for treating cancers and viral diseases?
Given Mr. Chemerow's background, how will AIM ImmunoTech Inc. AIM address any potential risks associated with the approval process for its investigational drug, Ampligen?
What measures is AIM ImmunoTech Inc. AIM implementing to ensure that its Board effectively supports its mission in the immuno-pharma space, especially with Mr. Chemerow's recent appointment?
**MWN-AI FAQ is based on asking OpenAI questions about AIM ImmunoTech Inc. (NYSE: AIM).
NASDAQ: AIM
AIM Trading
57.55% G/L:
$0.4038 Last:
448,184,778 Volume:
$0.2756 Open:
